Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CheckMate 7DX
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
- NCT04100018 ↗
- Completed
- Bristol-Myers Squibb
- Focused
We haven't built an HCP commentary report on CheckMate 7DX (nivolumab in androgen receptor pathway inhibitor-pretreated metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CheckMate 7DX so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Prostate Cancer
- Interventions
- Nivolumab; Prednisone; Docetaxel; Placebo
- Arms
- Arm A: Nivolumab + docetaxel + prednisone · Experimental
- Arm B: Placebo + docetaxel + prednisone · Placebo comparator
- Enrollment
- 1,030
- Primary outcomes
- Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3)
- Overall Survival (OS)
- Sponsor
- Bristol-Myers Squibb
- Start
- Feb 6, 2020
- Primary completion
- Jun 1, 2023
- Results posted
- Yes
- Registry record
- NCT04100018 · updated Jun 12, 2025
Publications
linked from the registry- Fizazi K, Saad F, Alonso-Gordoa T, Zurawski B, Barthelemy P, Voog E, Javier Cutuli H, Buchler T, Ye D, Castellano D, Kwiatkowski M, Arslan C, Richardet M, Alifrangis C, Goh JC, Vianna K, Han W, Hatano K, Todenhofer T, Retz M, Srivastava A, Jin C, Gupta S, Trandafirescu G, Campos A, Lee CW, van Kooten Losio M, Subudhi SK. Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2026 Jan;27(1):68-78. doi: 10.1016/S1470-2045(25)00566-2. PubMed 41449150